Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: As sulfadiazine 167 mg, sulfadimidine 167 mg, sulfamerazine 167 mg combination per tablet: Initially 4-8 tablets, then 2 tablets every 6 hr.
Renal Impairment
Dose reduction may be needed.
Hepatic Impairment
Dose reduction may be needed.
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE. Pregnancy and lactation; infants ≤2 mth.
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency (at risk of hemolytic reactions); elderly; ensure adequate fluid intake to reduce risk of crystalluria. Discontinue use if rash develops.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson Syndrome, toxic epidermal necrolysis, anaphylaxis.
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased risk of crystalluria by compounds that render the urine acidic.
Lab Interference
Interference with tests for urea, creatinine, urinary glucose and urobilinogen.
Description: Sulfamerazine is a short-acting sulfonamide that interferes with the synthesis of nucleic acids in sensitive organisms by blocking the conversion of p-aminobenzoic acid (PABA) to the co-enzyme dihydrofolic acid. Its action is bacteriostatic, bactericidal effect may be exerted where concentrations of thymine are low in the surrounding medium. It is usually administered with other sulfonamides or with trimethoprim.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfamerazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in